Servier India has recently launched a significant biomarker testing initiative. This program aims to improve early diagnosis and access to precision oncology testing for Acute Myeloid Leukaemia (AML) and Cholangiocarcinoma (CCA) across India. Servier India collaborated with MedGenome and Strand Life Sciences for this patient-centric approach.
Under this initiative, a specialized panel of biomarker tests for AML, an aggressive blood cancer, and CCA, a rare bile duct cancer, will be available at subsidized rates nationwide. Furthermore, patients in the government sector will receive IDH1 and IDH2 mutation tests for both cancers free of cost, thus removing a significant financial barrier. This strategic move targets crucial genetic markers that guide treatment decisions, fostering better patient outcomes. For a deeper understanding of cancer treatments and diagnostics, consider exploring our Oncology Speciality Courses.
Expanding Access to Biomarker Testing
This initiative directly addresses the current disparity in molecular testing access. Presently, such advanced diagnostics remain largely confined to urban centers, which consequently limits timely and accurate diagnoses for many patients across the country. Aurelien Breton, Managing Director, Servier India, emphasized the importance of early molecular testing in cancers like AML and CCA. It supports informed treatment decisions, therefore potentially improving survival rates. This collaboration represents a firm commitment to making precision diagnostics more accessible, ensuring that geography or financial status does not dictate access to timely and precise diagnosis.
The Role of Precision Diagnosis
Precision oncology fundamentally starts with a precision diagnosis. Pratima Tripathi, Commercial Director – Oncology, Servier India, highlighted that identifying key genetic mutations is essential for guiding effective treatment decisions for both AML and Cholangiocarcinoma. Through this program, Servier India endeavors to integrate advanced biomarker testing into routine oncology practice. This integration will enable physicians to make evidence-based treatment choices, ultimately leading to improved patient outcomes. The IDH1 and IDH2 mutations are particularly significant, as they are key genetic markers that help direct targeted therapies. To stay at the forefront of advancements in this field, professionals can benefit from our Certification Course In Clinical Oncology.
Holistic Patient Support
The new biomarker testing program is part of the broader Servier Care patient support platform. This comprehensive platform offers various forms of assistance, including financial aid, free drug support, and subsidized diagnostic services for eligible patients. Thus, Servier India ensures holistic and equitable care where legally permissible, reinforcing its dedication to patient well-being beyond just diagnostics. Aliasgar Patanwala, Market Access Lead, Servier India, also noted that collaboration across the healthcare chain is vital for effective access, focusing on strengthening coordination between laboratories, clinicians, and patient pathways.
Frequently Asked Questions
Q1: What is the primary goal of Servier India’s new initiative?
A: Servier India’s initiative aims to improve early diagnosis and access to affordable biomarker testing for IDH-mutated Acute Myeloid Leukaemia (AML) and Cholangiocarcinoma (CCA) patients across India by bridging the access gap in molecular testing.
Q2: Which biomarker tests are offered free of cost under this program?
A: The IDH1 and IDH2 mutation tests for both AML and Cholangiocarcinoma will be offered free of cost to patients receiving care in the government sector.
Q3: What broader patient support is available through Servier Care?
A: The Servier Care platform provides eligible patients with financial assistance, free drug support, and subsidized diagnostic services, ensuring comprehensive and equitable care.
References
- Servier India Launches Affordable Biomarker Testing Initiative for IDH-MutatedAML and Cholangiocarcinoma – ETHealthworld
- Servier India rolls out affordable biomarker testing for leukaemia and bile duct cancer patients – BusinessToday
- Servier India inks partnership with MedGenome and Strand Life Sciences – Pharmabiz.com
- Servier India with MedGenome and Strand Life Sciences to advance biomarker testing for IDH-mutated AML & CCA – Pharmabiz.com
- Free genetic testing for blood cancer now in India. Here’s how and where – India Today
- Servier India Partners with MedGenome & Strand Life Sciences, Expanding AML & CCA Testing – eHealth Magazine
Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.